Luc Van Kaer Selected Research

Cholinergic Receptors

6/2010	Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia.
5/2006	Autoreactive T cells mediate NK cell degeneration in autoimmune disease.
12/2005	Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Luc Van Kaer Research Topics

Disease

21	Inflammation (Inflammations) 01/2022 - 04/2003
12	Tuberculosis (Tuberculoses) 01/2020 - 11/2011
12	Infections 11/2019 - 04/2002
10	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2022 - 04/2002
8	Neoplasms (Cancer) 01/2017 - 03/2002
7	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 05/2002
6	Leukemia 01/2017 - 11/2008
6	Atherosclerosis 04/2013 - 06/2004
5	Multiple Sclerosis 01/2022 - 06/2004
5	Obesity 01/2022 - 05/2012
4	Disease Progression 01/2021 - 06/2004
4	Colitis 01/2017 - 01/2011
4	Insulin Resistance 01/2016 - 05/2012
4	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2011 - 06/2004
3	Sepsis (Septicemia) 03/2021 - 01/2015
3	Reinfection 01/2017 - 06/2014
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 11/2011 - 06/2004
3	Myasthenia Gravis 06/2010 - 12/2005
2	Malaria 01/2019 - 03/2002
2	Communicable Diseases (Infectious Diseases) 01/2017 - 11/2016
2	Uveitis 12/2016 - 08/2003
2	Pulmonary Tuberculosis 11/2016 - 01/2009
2	Bacterial Infections (Bacterial Infection) 06/2015 - 09/2003
2	Virus Diseases (Viral Diseases) 02/2013 - 02/2011
2	Hepatitis 06/2008 - 10/2004
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 04/2005 - 06/2004
2	Lupus Nephritis 04/2005 - 08/2003
2	Dermatitis 06/2004 - 10/2003
2	Granuloma 07/2002 - 01/2002
1	Lewis Lung Carcinoma 01/2021
1	Parasitemia 01/2019
1	Hyperlactatemia 01/2019
1	Fibrosis (Cirrhosis) 01/2018
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2018
1	Sarcoidosis (Schaumann Disease) 01/2018
1	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2018
1	Cadaver (Cadavers) 01/2017

Drug/Important Bio-Agent (IBA)

19	CytokinesIBA 01/2022 - 05/2002
18	alpha-galactosylceramideIBA 02/2009 - 03/2002
15	AntigensIBA 01/2017 - 03/2002
13	GlycolipidsIBA 01/2022 - 01/2002
7	Interleukin-10 (Interleukin 10)IBA 10/2019 - 01/2011
7	LigandsIBA 01/2018 - 05/2002
6	LipidsIBA 01/2020 - 12/2004
5	Interleukin-17 (Interleukin 17)IBA 11/2019 - 01/2011
5	Interleukin-4 (Interleukin 4)IBA 11/2019 - 04/2005
5	VaccinesIBA 11/2016 - 03/2002
4	Proteins (Proteins, Gene)FDA Link 01/2019 - 06/2007
3	LipopolysaccharidesIBA 03/2021 - 11/2006
3	Isoniazid (Ftivazide)FDA LinkGeneric 01/2020 - 10/2014
3	Apolipoproteins E (ApoE)IBA 04/2013 - 10/2004
3	ApolipoproteinsIBA 04/2013 - 10/2004
3	Histocompatibility Antigens Class IIBA 10/2011 - 03/2005
3	Cholinergic ReceptorsIBA 06/2010 - 12/2005
3	Concanavalin AIBA 06/2008 - 10/2004
2	Class III Phosphatidylinositol 3-KinasesIBA 01/2022 - 01/2021
2	Myelin-Oligodendrocyte GlycoproteinIBA 01/2022 - 01/2021
2	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2022 - 01/2021
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021 - 01/2013
2	CurcuminIBA 11/2019 - 01/2017
2	AntibodiesIBA 01/2017 - 10/2009
2	Peptides (Polypeptides)IBA 12/2016 - 04/2002
2	interstitial retinol-binding proteinIBA 12/2016 - 08/2003
2	Interleukin-12 (IL 12)IBA 06/2015 - 06/2008
2	Pharmaceutical PreparationsIBA 06/2014 - 01/2011
2	Messenger RNA (mRNA)IBA 02/2013 - 12/2012
2	Monoclonal AntibodiesIBA 04/2011 - 11/2006
2	Galactosylceramides (Galactocerebrosides)IBA 02/2011 - 01/2002
2	Neutralizing AntibodiesIBA 01/2011 - 10/2004
2	AutoantigensIBA 01/2011 - 12/2005
2	Immunoglobulin G (IgG)IBA 01/2011 - 01/2008
2	thymus-leukemia antigensIBA 11/2010 - 11/2008
2	EpitopesIBA 01/2008 - 10/2004
2	HydrocarbonsIBA 04/2005 - 08/2003
2	pristane (pristan)IBA 04/2005 - 08/2003
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022
1	GalactosamineIBA 03/2021
1	ChromatinIBA 03/2021
1	SilverIBA 01/2021
1	perchlorateIBA 01/2021
1	EstersIBA 01/2021
1	tetramethylrhodamine (T 489)IBA 01/2021
1	Propidium (Propidium Iodide)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	SAR405IBA 01/2021
1	Sirolimus (Rapamycin)FDA Link 01/2020
1	Interferon-gamma (Interferon, gamma)IBA 11/2019
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2019
1	graphene oxideIBA 01/2018
1	Bleomycin (Blenoxane)FDA LinkGeneric 01/2018
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2018
1	bergeninIBA 01/2017
1	Granzymes (Granzyme)IBA 01/2017
1	GoldIBA 01/2017
1	MucinsIBA 01/2017
1	Antitubercular AntibioticsIBA 01/2017
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2017
1	Freund's AdjuvantIBA 12/2016

Therapy/Procedure

10	Therapeutics 01/2018 - 01/2005
8	Immunotherapy 01/2022 - 06/2004